Date | Time | Source | Announcement |
---|---|---|---|
24 Aug 2006 | 07:00 AM | Collaboration Agreement | |
09 Aug 2006 | 08:03 AM | Supplementary consideration shares | |
08 Aug 2006 | 08:00 AM | First Day of Dealings | |
07 Aug 2006 | 12:58 PM | Result of EGM | |
14 Jul 2006 | 02:20 PM | Final Results | |
14 Jul 2006 | 12:00 PM | Propsd Aqstn & notice of EGM | |
13 Jul 2006 | 09:30 AM | Stmnt re Proposed Transaction | |
07 Jul 2006 | 04:07 PM | Directorate Change | |
05 May 2006 | 11:24 AM | Result of EGM | |
19 Apr 2006 | 03:13 PM | Further re Issue of Equity | |
19 Apr 2006 | 08:08 AM | Holding(s) in Company | |
13 Apr 2006 | 05:28 PM | Holding(s) in Company | |
12 Apr 2006 | 07:44 AM | Issue of Equity | |
09 Mar 2006 | 02:19 PM | Holding(s) in Company | |
26 Jan 2006 | 08:23 AM | Interim Results | |
24 Aug 2005 | 07:00 AM | Final Results | |
25 Jul 2005 | 07:57 AM | Board change & trading update | |
17 Jun 2005 | 11:09 AM | Business Strategy | |
25 May 2005 | 04:55 PM | Issue of Equity | |
11 Apr 2005 | 11:00 AM | EGM Statement | |
23 Mar 2005 | 09:22 AM | Issue of Equity | |
15 Mar 2005 | 03:32 PM | Notice of EGM | |
28 Jan 2005 | 04:48 PM | Interim Results | |
25 Oct 2004 | 11:27 AM | Holding(s) in Company | |
30 Sep 2004 | 02:11 PM | Director Shareholding | |
29 Sep 2004 | 09:08 AM | Annual Report and Accounts | |
23 Jun 2004 | 03:52 PM | Holding(s) in Company | |
29 Jan 2004 | 05:39 PM | Interim Results | |
09 Sep 2003 | 04:25 PM | Holding(s) in Company | |
08 Sep 2003 | 07:00 AM | First day dealings |
Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics.
It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.
Avacta Group share price launched at 5,448p in 2003.